An interventional study of PNF and Sham in COPD, sponsored by Universidade Federal do Pampa. Status unknown at 1 site in Brazil. Open to male participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-26.
Sponsored by Universidade Federal do Pampa · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies in Pulmonary Disease, Chronic Obstructive with a site in Brazil — 20 open to participants now, 24 under way, 7 of them phase 3. Pulmonary Disease, Chronic Obstructive · Brazil.
Among the 144 studies in Pulmonary Disease, Chronic Obstructive with a site in Brazil, this one is the 57th largest by enrollment of the 124 interventional ones that give a count, is one of 9 that started in 2017, is one of 64 with no phase, and was the 92nd registered.
5,522 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →20 of the 144 studies in Pulmonary Disease, Chronic Obstructive with a site in Brazil are open now. Recruiting first, the newest first:
Federal University of Health Science of Porto Alegre · Sites in Brazil
Ages 18–90 · Healthy volunteers
Chiesi Farmaceutica Ltda. · Sites in Brazil
Ages 40+
Sanofi · Sites in Brazil, United States, Argentina and 19 more countries
Ages 40–85
Sanofi · Sites in Brazil, United States, Argentina and 23 more countries
Ages 40–80
Sanofi · Sites in Brazil, United States, Argentina and 22 more countries
Ages 40–80
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 36 · Phase 4 16
First in 2000; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is close to the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 59 across the 124 interventional studies, 301 across the 20 observational. Of the 89 that completed or were terminated, 32 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 144 have an industry lead sponsor. The 10 most frequent:
Universidade Federal do Pampa is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Universidade Federal do Pampa has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
6 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07050823University College, LondonMitigating Chronic Respiratory Disease Through the Lens of Multi-Morbidity | 2026-12 |
| NCT07868211Júnea Regina Pires DrewsEffect of Dietary Fiber Supplementation on Systemic Inflammation and Clinical Parameters in COPD | 2027-04 |
| NCT07406048Chiesi Farmaceutica Ltda.Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients | 2027-06-30 |
| NCT07134855University College, LondonMitigating Chronic Respiratory Disease Through the Lens of Multimorbidity (MARES3) | 2027-07-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 144 studies in Pulmonary Disease, Chronic Obstructive with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the activation of accessory respiratory muscles and the effects of stretching these muscles in patients with COPD.
All subjects (sixty men) will perform spirometry, measure of inspiratory capacity (IC) and maximal inspiratory and expiratory pressures (MIP and MEP). Baseline blood pressure (BP), respiratory rate (RR), heart rate (HR), sensation of dyspnea (Borg Scale) and oxygen saturation (pulse oximetry, SpO2) will be collected prior to the performance of pulmonary function tests.
The electrical activity of the scalene (ESC), sternocleidomastoid (SCM) and external intercostal muscles (INTER) will be measured by surface electromyography (sEMG) at rest and during the maneuvers of IC, MIP and MEP.
Control group: The control group will perform isotonic concentric contraction of the biceps (two sets of five push-ups elbow in both arms) with the individual sitting in a chair with back support.
Intervention group: The contract-relax method of proprioceptive neuromuscular facilitation (PNF) technique will be used for stretching of ESC, ECM and external intercostals muscles. The contraction of agonist muscles against the resistance imposed by the physiotherapist (isometric contraction) is maintained for 6 seconds. After that, the patient will be asked to relax the muscles for 6 seconds without losing range of motion, and then the muscle will be lengthened. This procedure is repeated until the maximum amplitude of motion of the neck and upper limb is reached. The stretching will be performed on the right and left sides of the body.
Statistical analysis will be carried out with the Statistical Package for the Social Sciences, version 18.0 (SPSS Inc., Chicago, IL, USA). Normality of data distribution will be assessed by the Shapiro-Wilk test.
Values will be presented as mean ± standard deviation (SD) or median (25-75%). To compare the differences between the baseline characteristics between the groups the t test for independent samples will be used. The effect of the intervention will be evaluated by paired t test. For the analysis of the electromyographic signal will be use the Wilcoxon T test. Statistical significance is accepted at p \< 0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD - PNF
Procedure: PNF
COPD - sham
Procedure: Sham
Individuals Without COPD - PNF
Procedure: PNF
Individuals Without COPD - sham
Procedure: Sham
The contract-relax method of proprioceptive neuromuscular facilitation (PNF) technique will be used for stretching of ESC, ECM and external intercostals muscles. The contraction of agonist muscles against the resistance imposed by the physiotherapist (isometric contraction) will be maintained for 6 seconds. After that, the patient is oriented to relax the muscles for 6 seconds without losing range of motion, and then the muscle will be lengthened. This procedure is repeated until the maximum amplitude of motion of the neck and upper limb is reached. The stretching will be performed on the right and left sides of the body.
Isotonic concentric contraction of the biceps (two sets of five push-ups elbow in both arms) with the individual sitting in a chair with back support.
Change in inspiratory capacity
Change in inspiratory capacity
Time frame: One day
Change in maximal respiratory pressure (MIP and MEP)
Change in maximal respiratory pressure (MIP and MEP)
Time frame: One day
Change in electromyographic activity of accessory respiratory muscles
Change in electromyographic activity of accessory respiratory muscles
Time frame: One Day
Started Dec 2017 (actual). Primary completion is estimated for Dec 2018, 12 months after the start.
Of 1,095 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.
Counting every sponsor, half of 1,182 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Universidade Federal do Pampa